Utility of 64 Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on 68 Ga-PSMA-11 PET/CT
Journal of Nuclear Medicine · 2024
DOI: 10.2967/jnumed.124.267881 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2024. Verfasst von Sherrington Li und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Prostatic Neoplasms, Gallium Radioisotopes, Bombesin. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
Despite a high detection rate of 68Ga-prostate-specific membrane antigen (PSMA) PET/CT in biochemical recurrence (BCR) of prostate cancer, a significant proportion of men have negative 68Ga-PSMA-11 PET/CT results. Gastrin-releasing peptide receptor, targeted by the copper-chelated bombesin analog 64Cu-sarcophagine-bombesin (SAR-BBN) PET/CT, is also overexpressed in prostate cancer. In this prospective imaging study, we investigate the detection rate of 64Cu-SAR-BBN PET/CT in patients with BCR and negative or equivocal 68Ga-PSMA-11 PET/CT results.
Methods
Men with confirmed adenocarcinoma of the prostate, prior definitive therapy, and BCR (defined as a prostate-specific antigen [PSA] level > 0.2 ng/mL) with negative or equivocal 68Ga-PSMA-11 PET/CT results within 3 mo were eligible for enrollment. 64Cu-SAR-BBN PET/CT scans were acquired at 1 and 3 h after administration of 200 MBq of 64Cu-SAR-BBN, with further delayed imaging undertaken optionally at 24 h. PSA (ng/mL) was determined at baseline. All PET (PSMA and bombesin) scans were assessed visually. Images were read with masking of the clinical results by 2 experienced nuclear medicine specialists, with a third reader in cases of discordance. Accuracy was defined using a standard of truth that included biopsy confirmation, confirmatory imaging, or response to targeted treatment.
Results
Twenty-five patients were enrolled. Prior definitive therapy was radical prostatectomy (n = 24, 96%) or radiotherapy (n = 1, 4%). The median time since definitive therapy was 7 y (interquartile range [IQR], 4-11 y), and the Gleason score was 7 or less (n = 15, 60%), 8 (n = 3, 12%), or 9 (n = 7, 28%). The median PSA was 0.69 ng/mL (IQR, 0.28-2.45 ng/mL). Baseline PSMA PET scans were negative in 19 patients (76%) and equivocal in 6 (24%). 64Cu-SAR-BBN PET-avid disease was identified in 44% (11/25): 12% (3/25) with local recurrence, 20% (5/25) with pelvic node metastases, and 12% (3/25) with distant metastases. The κ-score between readers was 0.49 (95% CI, 0.16-0.82). Patients were followed up for a median of 10 mo (IQR, 9-12 mo). Bombesin PET/CT results were true-positive in 5 of 25 patients (20%), false-positive in 2 of 25 (8%), false-negative in 7 of 25 (28%), and unverified in 11 of 25 (44%).
Conclusion
64Cu-SAR-BBN PET/CT demonstrated sites of disease recurrence in 44% of BCR cases with negative or equivocal 68Ga-PSMA-11 PET/CT results. Further evaluation to confirm diagnostic benefit is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia.
- St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
- Genesis Cancer Care, Sydney, New South Wales, Australia.
- Department of Radiation Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
- Faculty of Medicine, University of Sydney, Sydney, New South Wales, Australia.
- Kinghorn Cancer Care Centre, St. Vincent's Hospital, Sydney, New South Wales, Australia.
Zitieren
APA
Li, S., Nguyen, A., Counter, W., John, N. C., De Leon, J., Hruby, G., Joshua, A. M., Stricker, P., Crumbaker, M., Ayati, N., Chan, L., Sabahi, Z., Swiha, M., Kneebone, A., Wong, K., Liu, V., Sharma, S., Agrawal, S., & Emmett, L. M. (2024). Utility of 64 Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on 68 Ga-PSMA-11 PET/CT. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.267881
Vancouver
Li S, Nguyen A, Counter W, John NC, De Leon J, Hruby G, et al. Utility of 64 Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on 68 Ga-PSMA-11 PET/CT. Journal of Nuclear Medicine. 2024. doi:10.2967/jnumed.124.267881
BibTeX
@article{Li2024,
author = {Li, Sherrington and Nguyen, Andrew and Counter, William and John, Nikeith C and De Leon, Jeremiah and Hruby, George and Joshua, Anthony M and Stricker, Phillip and Crumbaker, Megan and Ayati, Narjess and Chan, Lyn and Sabahi, Zahra and Swiha, Mina and Kneebone, Andrew and Wong, Keith and Liu, Victor and Sharma, Shikha and Agrawal, Shikha and Emmett, Louise M},
title = {Utility of 64 Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on 68 Ga-PSMA-11 PET/CT},
journal = {Journal of Nuclear Medicine},
year = {2024},
doi = {10.2967/jnumed.124.267881}
}
EUVIMED